News & Updates

Canagliflozin holds promise against MAFLD in T2D patients
Canagliflozin holds promise against MAFLD in T2D patients
27 Oct 2023 byStephen Padilla

Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.

Canagliflozin holds promise against MAFLD in T2D patients
27 Oct 2023
High red meat consumption increases risks of CVD and diabetes
High red meat consumption increases risks of CVD and diabetes
27 Oct 2023
Histologic margin status predicts relapse in lentigo maligna melanoma
Histologic margin status predicts relapse in lentigo maligna melanoma
26 Oct 2023